 A message from SCD Media LLC |
| NanoViricides’ NV-387 Could Redefine How Viral Infections Are Treated, Offering Potential Breakthrough in Multi-Billion-Dollar Antiviral Market! NanoViricides, Inc. (NYSE American: NNVC) is on the verge of transforming the antiviral landscape with its lead clinical-stage drug, NV-387. This broad-spectrum antiviral is advancing through Phase II trials and is designed to treat viral infections without the need to first identify the causative virus, potentially revolutionizing how respiratory viral infections are managed worldwide. NV-387 has already demonstrated superior efficacy in animal models against Influenza, RSV, COVID-19, and MPox compared to existing treatments, with excellent safety and tolerability confirmed in Phase I human trials. In addition, NNVC is pursuing orphan drug designations for MPox, Smallpox, and Measles, opening opportunities for seven years of market exclusivity, FDA fee waivers, and potential Priority Review Vouchers valued at over $150 million, highlighting NV-387’s substantial market potential. Beyond NV-387, NNVC is advancing a diversified pipeline including NV-HHV-1 for Shingles and herpes infections, as well as anti-HIV therapies showing superior results in humanized animal models. With proprietary nanoviricide technology that mimics virus-binding sites to neutralize viruses while avoiding resistance, NNVC is positioned to disrupt multiple viral markets, including MPox, Smallpox, RSV, Influenza, and COVID-19. Strategic milestones in the coming year, including Phase II trial completions and regulatory filings, could further validate NV-387’s potential and drive shareholder value. |
| This is a paid advertisement provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's does not necessarily endorse this product nor is it responsible for the content of this advertisement. Schaeffer's makes no guarantee or warranty about what is advertised above. |